| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Tadashi Arao, Yosuke Okada, Fumi Uemura, Shigeru Nishizawa, Yoshiya Tanak. A Case of Acromegaly in which a Pituitary Gland Tumor was Reduced Significantly by Administering Octreotide Long Acting Release (LAR) and Could Be Removed Surgically. Journal of UOEH. vol 39. issue 3. 2018-01-29. PMID:28904276. |
she was diagnosed with acromegaly based on the characteristic physical findings, gh excess, high igf-1, lack of gh suppression during the 75-g ogtt, and the presence of a pituitary tumor. |
2018-01-29 |
2023-08-13 |
Not clear |
| Tadashi Arao, Yosuke Okada, Fumi Uemura, Shigeru Nishizawa, Yoshiya Tanak. A Case of Acromegaly in which a Pituitary Gland Tumor was Reduced Significantly by Administering Octreotide Long Acting Release (LAR) and Could Be Removed Surgically. Journal of UOEH. vol 39. issue 3. 2018-01-29. PMID:28904276. |
after three doses, her gh and igf-1 levels decreased to 2.19 ng/ml (1.69 during the 75-g ogtt) and 205 ng/ml, respectively, meeting cure criteria for acromegaly. |
2018-01-29 |
2023-08-13 |
Not clear |
| Tadashi Arao, Yosuke Okada, Fumi Uemura, Shigeru Nishizawa, Yoshiya Tanak. A Case of Acromegaly in which a Pituitary Gland Tumor was Reduced Significantly by Administering Octreotide Long Acting Release (LAR) and Could Be Removed Surgically. Journal of UOEH. vol 39. issue 3. 2018-01-29. PMID:28904276. |
in this case, a decrease in gh and igf-1 levels, tumor shrinkage, and resolution of cavernous sinus invasion allowed the patient to undergo surgery with curative intent (the first-line treatment for acromegaly) without postoperative complications. |
2018-01-29 |
2023-08-13 |
Not clear |
| Fady Hannah-Shmouni, Giampaolo Trivellin, Constantine A Strataki. Genetics of gigantism and acromegaly. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. vol 30-31. 2018-01-26. PMID:27657986. |
gigantism and acromegaly are rare disorders that are caused by excessive gh secretion and/or high levels of its mediator, igf-1. |
2018-01-26 |
2023-08-13 |
Not clear |
| Morali D Sharma, Anh V Nguyen, Spandana Brown, Richard J Robbin. Cardiovascular Disease in Acromegaly. Methodist DeBakey cardiovascular journal. vol 13. issue 2. 2018-01-16. PMID:28740584. |
in patients with acromegaly, chronic excess of growth hormone (gh) and insulin-like growth factor-1 (igf-1) leads to the development of acromegalic cardiomyopathy. |
2018-01-16 |
2023-08-13 |
Not clear |
| Kjell Öberg, Steven W J Lambert. Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future. Endocrine-related cancer. vol 23. issue 12. 2017-12-29. PMID:27697899. |
acromegaly is a hormonal disorder that arises when the pituitary gland secretes excess growth hormone (gh), which in turn stimulates a concomitant increase in serum insulin-like growth factor 1 (igf-1) levels. |
2017-12-29 |
2023-08-13 |
Not clear |
| Stefano Frara, Filippo Maffezzoni, Gherardo Mazziotti, Andrea Giustin. Current and Emerging Aspects of Diabetes Mellitus in Acromegaly. Trends in endocrinology and metabolism: TEM. vol 27. issue 7. 2017-12-18. PMID:27229934. |
diabetes mellitus is a frequent complication of acromegaly, a disease characterized by chronic hypersecretion of growth hormone (gh) by a pituitary adenoma. |
2017-12-18 |
2023-08-13 |
Not clear |
| Stefano Frara, Filippo Maffezzoni, Gherardo Mazziotti, Andrea Giustin. Current and Emerging Aspects of Diabetes Mellitus in Acromegaly. Trends in endocrinology and metabolism: TEM. vol 27. issue 7. 2017-12-18. PMID:27229934. |
moreover, the presence of diabetes may also influence therapeutic decision making in acromegaly, since traditional and newly developed drugs used in this clinical setting may impact glucose metabolism regardless of control of gh hypersecretion. |
2017-12-18 |
2023-08-13 |
Not clear |
| Noriyuki Katsumat. Standardization of Growth Hormone and Insulin-like Growth Factor-I Measurements. Pediatric endocrinology reviews : PER. vol 14 Suppl 1. issue Suppl 1. 2017-12-11. PMID:28516748. |
measurement of the levels of growth hormone (gh) and its related factor insulin-like growth factor i (igf-i) is essential for the diagnosis and treatment of gh deficiency (ghd) and conditions related to excess gh such as acromegaly and pituitary gigantism. |
2017-12-11 |
2023-08-13 |
human |
| Miriam A Bredella, Melanie Schorr, Laura E Dichtel, Anu V Gerweck, Brian J Young, Whitney W Woodmansee, Brooke Swearingen, Karen K Mille. Body Composition and Ectopic Lipid Changes With Biochemical Control of Acromegaly. The Journal of clinical endocrinology and metabolism. vol 102. issue 11. 2017-12-04. PMID:28945897. |
acromegaly is characterized by growth hormone (gh) and insulinlike growth factor-1 (igf-1) hypersecretion, and gh and igf-1 play important roles in regulating body composition and glucose homeostasis. |
2017-12-04 |
2023-08-13 |
Not clear |
| Jakob Dal, Marianne Klose, Ansgar Heck, Marianne Andersen, Caroline Kistorp, Eigil H Nielsen, Jens Bollerslev, Ulla Feldt-Rasmussen, Jens O L Jørgense. Targeting either GH or IGF-I during somatostatin analogue treatment in patients with acromegaly: a randomized multicentre study. European journal of endocrinology. vol 178. issue 1. 2017-11-27. PMID:28993415. |
targeting either gh or igf-i during somatostatin analogue treatment in patients with acromegaly: a randomized multicentre study. |
2017-11-27 |
2023-08-13 |
Not clear |
| Jakob Dal, Marianne Klose, Ansgar Heck, Marianne Andersen, Caroline Kistorp, Eigil H Nielsen, Jens Bollerslev, Ulla Feldt-Rasmussen, Jens O L Jørgense. Targeting either GH or IGF-I during somatostatin analogue treatment in patients with acromegaly: a randomized multicentre study. European journal of endocrinology. vol 178. issue 1. 2017-11-27. PMID:28993415. |
discordant gh and igf-i values are frequent in acromegaly. |
2017-11-27 |
2023-08-13 |
Not clear |
| T Rubinek, D Modan-Mose. Klotho and the Growth Hormone/Insulin-Like Growth Factor 1 Axis: Novel Insights into Complex Interactions. Vitamins and hormones. vol 101. 2017-10-30. PMID:27125739. |
defects in the axis' activity during childhood result in growth abnormalities, while increased secretion of gh from the pituitary results in acromegaly. |
2017-10-30 |
2023-08-13 |
mouse |
| Christina Kanaka-Gantenbein, Christina Kogia, Mohamed Badawy Abdel-Naser, George P Chrouso. Skin manifestations of growth hormone-induced diseases. Reviews in endocrine & metabolic disorders. vol 17. issue 3. 2017-10-04. PMID:27571787. |
both growth hormone (gh) excess, as in the case of acromegaly in adults, or gigantism in growing children, and gh deficiency states lead to skin manifestations. |
2017-10-04 |
2023-08-13 |
human |
| Jean-Christophe François, Saba Aïd, Zayna Chaker, Philippe Lacube, Jie Xu, Racha Fayad, Francine Côté, Patrick Even, Martin Holzenberge. Disrupting IGF Signaling in Adult Mice Conditions Leanness, Resilient Energy Metabolism, and High Growth Hormone Pulses. Endocrinology. vol 158. issue 7. 2017-09-29. PMID:28881863. |
endocrine gh and igf-1 were strongly upregulated without causing acromegaly. |
2017-09-29 |
2023-08-13 |
mouse |
| G A Kanakis, A Chrisoulidou, A Bargiota, Z A Efstathiadou, L Papanastasiou, A Theodoropoulou, S K Tigas, D A Vassiliadi, S Tsagarakis, M Alevizak. The ongoing challenge of discrepant growth hormone and insulin-like growth factor I results in the evaluation of treated acromegalic patients: a systematic review and meta-analysis. Clinical endocrinology. vol 85. issue 5. 2017-09-22. PMID:27292418. |
growth hormone (gh) and insulin-like growth factor i (igf-i) are the principal biomarkers used to assess disease activity in acromegaly, and any discrepancy between them renders interpretation of results inconclusive. |
2017-09-22 |
2023-08-13 |
Not clear |
| Jan-Shun Chang, Ham-Min Tseng, Tien-Chun Chan. Serial follow-up of presurgical treatment using pasireotide long-acting release with or without octreotide long-acting release for naïve active acromegaly. Journal of the Formosan Medical Association = Taiwan yi zhi. vol 115. issue 6. 2017-08-21. PMID:27117887. |
the aim of the present study was to evaluate the serial changes of gh and igf-1 in seven patients with naïve, active acromegaly following presurgical treatment of the somatostatin analog pasireotide long-acting release (lar) and octreotide lar. |
2017-08-21 |
2023-08-13 |
Not clear |
| Pedro W Rosario, Maria R Calsolar. Elevated IGF-1 with GH suppression after an oral glucose overload: incipient acromegaly or false-positive IGF-1? Archives of endocrinology and metabolism. vol 60. issue 6. 2017-08-16. PMID:27982199. |
elevated igf-1 with gh suppression after an oral glucose overload: incipient acromegaly or false-positive igf-1? |
2017-08-16 |
2023-08-13 |
Not clear |
| Pedro W Rosario, Maria R Calsolar. Elevated IGF-1 with GH suppression after an oral glucose overload: incipient acromegaly or false-positive IGF-1? Archives of endocrinology and metabolism. vol 60. issue 6. 2017-08-16. PMID:27982199. |
to report the evolution of patients with a suggestive clinical scenario and elevated serum insulin-like growth factor-1 (igf-1), but growth hormone (gh) suppression in the oral glucose tolerance test (ogtt), in whom acromegaly was not initially excluded. |
2017-08-16 |
2023-08-13 |
Not clear |
| Luis V Syro, Fabio Rotondo, Carlos A Serna, Leon D Ortiz, Kalman Kovac. Pathology of GH-producing pituitary adenomas and GH cell hyperplasia of the pituitary. Pituitary. vol 20. issue 1. 2017-07-10. PMID:27586499. |
gh cell hyperplasia can also be associated with acromegaly in patients with extrapituitary gh-releasing hormone secreting tumors or in familial pituitary tumor syndromes. |
2017-07-10 |
2023-08-13 |
Not clear |